Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin D sterols in dialysis patients

NDT Plus

Volumn 1, Issue SUPPL.1, 2008, Pages

  Bushinsky, David A ^a   Messa, Piergiorgio ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Calcimimetics; Calcium; Parathyroid hormone; Phosphorus; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CINACALCET; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; VITAMIN D;

BONE DISEASE; BONE METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EARLY INTERVENTION; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOTHESIS; LOW DRUG DOSE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION;

EID: 39349103587     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm040     Document Type: Conference Paper

References (55)

1. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-F175
2. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocrine Rev 2005; 26: 662-687
3. Nishishita T, Okazaki T, Ishikawa T et al. A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J Biol Chem 1998; 273: 10901-10907
4. 3. Proc Natl Acad Sci USA 1992; 89: 8097-8101
5. 3 and the immune system. Proc Soc Exp Biol Med 1989; 191: 238-245
6. Yang S, Smith C, Prahl JM et al. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch Biochem Biophys 1993; 303: 98-106
7. 3 on CD34 progenitor cells in vitamin D deficiency rickets. Turk J Pediatr 2004; 46: 164-166
8. Yetgin S, Ozsoylu S. Myeloid metaplasia in vitamin D deficiency rickets. Scand J Haematol 1982; 28: 180-185
9. 3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol Endocrinol 2004; 18: 2685-2699
10. 3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588
11. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986; 7: 434-448
12. Cai Q, Tapper DN, Gilmour RF Jr et al. Modulation of the excitability of avian peripheral nerves by vitamin D: Relation to calbindin-D28k, calcium status and lipid composition. Cell Calcium 1994; 15: 401-410
13. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 7861-7864
14. Garcion E, Wion-Barbot N, Montero-Menei CN et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13: 100-105
15. Staud R, Vitamin D. More than just affecting calcium and bone. Curr Rheumatol Rep 2005; 7: 356-364
16. DeLuca HF, Zierold C. Mechanisms and functions of vitamin D. Nutr Rev 1998; 56: S4-S10; discussion S54-S75
17. Dusse AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28
18. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-894
19. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol 2005; 288: F253-F264
20. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993, 92: 1436-1443
21. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
22. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyper-parathyroidism. Kidney Int 1997; 51: 328-336
23. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
24. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
25. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
26. Brown AJ, Zhong M, Finch J et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996; 270: F454-F460
27. Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55: 1019-1027
28. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427-1432
29. Berl T, Berns AS, Hufer WE et al. 1,25-Dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 1978; 88: 774-780
30. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
31. Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: Its safety in a combination with oral calcium carbonate. J Ren Nutr 2003; 13: 78-83
32. Koshikawa S, Akizawa T, Kurokawa K et al. Clinical effect of intra-venous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses. Nephron 2002; 90: 413-423
33. Moe SM, Zekonis M, Harezlak J et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 2001; 38: 792-802
34. Akizawa T, Ohashi Y, Akiba T et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004; 8: 480-491
35. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187-1201
36. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
37. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
38. Malluche HH, Monier-Faugere MC, Koszewski NJ. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. Nephrol Dial Transplant 2002; 17(Suppl 10): 6-9
39. Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 2001; 38: S34-S40
40. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-112
41. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490
42. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
43. 3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
44. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study. Kidney Int 2005; 67: 1179-1187
45. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
46. Steddon SJ, Fan SL, Cunningham J. New prospects for the management of renal bone disease. Nephron Clin Pract 2005; 99: C1-c7
47. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int 2005; 67: 760-771
48. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-525
49. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HC1, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
50. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
51. Chertow G, Blumenthal S, Turner S et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006; 1: 305-312
52. Gonzalez M, Hutchison A, Girndt M et al. Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (Mimpara/Sensipar) [Abstract SP359]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK
53. Messa P, Villa G, Braun J et al. The OPTIMA study: Lower doses of cinacalcet (Mimpara/Sensipar) are required to achieve KDOQI secondary hyperparathyroidism (HPT) targets in patients with less severe disease [Abstract and Presentation MP324]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK.
54. Wilkie M, Salvadori M, De Meester J et al. The OPTIMA study: optimising the dose of vitamin D (vit D) in the presence of cinacalcet (Mimpara/Sensipar) to obtain maximum clinical benefit [Abstract SP358]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK.
55. Locatelli F, Macario F, Brink H et al. The OPTIMA study; efficacy of cinacalcet (Mimpara/Sensipar) treatment algorithm to treat dialysis patients with elevated PTH and calcium-phosphorus product (Ca x P) [Abstract SP357]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK.